Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQZGY5cVI0cnN5ZndidExXOHM1NzhTRUViNk5MVFN1Z1lJamxyUGtvYkFVRklHVlp6WnE1dlkyRUJlY3VacEF0TGhwOFVQRndYdGpNU0pTNUJPcDdNZlQ4UVROQlVUSE5PNjJobWZYTk0wZ1dYdHRueDV6ZUtrMzh1UjV1Rm1zQUlyZ0J0NTZBc2c4YTRGR2MwVE1yRy1LZFFRbmVj?oc=5" target="_blank">CAR T-Cell Therapy: The Next Paradigm in Multiple Sclerosis?</a>&nbsp;&nbsp;<font color="#6f6f6f">Medscape</font>
Jonas Brothers postpone Birmingham concert over weather concerns
Guardians' Steven Kwan Could Shake Up Winter Outfield Market
3 Storylines I'm Focused On in Warriors Preseason Game vs. Kings
PICTURES: Steffi Graf & Daughter Jaz Feature In Andre Agassi’s ‘Photo Dump’ As Carlos Alcaraz & Karl-Anthony Towns Make Surprise Appearance
Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1xdmlXeU51eS12YVpZR0M0eWlpSnliMTVDV0VtemNVdEtUUnd2X1pIaXc4d3plWXNLb244aUpXek1jMUhZdlJpTGVTdHpjOFU1MUVkNWVrNHU0UE5XVUQ0?oc=5" target="_blank">Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNbU0yVW9pS1M3dmJzckJkUzhRU3FXS29EZUR2dXlYQ0xudE93TDhQeldxUk9keDlPbVJyRFZkM2pCNUowaWU0OHNFOEJ0ZzhHRkRwRXJJNm9aa2REZF96ZG8teWw0Mzh1ajZjTUwxMURXRXowOFpQZWtDOTRlSFhHMUFDWFctNlRmSlBnWV9aTmQ4Q2dpT1pOVlk3ZzJDTFN2UWJTak1XbTdxXzJQV3c?oc=5" target="_blank">Dr Dhakal on the Investigation of Novel CAR T-Cell Therapy Approaches in Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">OncLive</font>
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOQmJ4NmYwSWU5NGtWalJ4d2o0U1VPc0F2TUVYaWVYUDBrdHpZZjh4TTdlUnRsRjhiN044RXN4bl9kMGdDNkVtSHBqTGw2RnNZb2JMb3FNT2xCUnJvb0h6d1Y0czFzT0NvTVNpU3F4MElDaXR3QlNsMFo5THhzQ3lEMkNBWUhEYlRxSVB1a0FDa0VhRS1mOE80N1NpWXZsU2dQSzZENFFSY2M3aktJUG5j?oc=5" target="_blank">BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxPMjVRejIwN25mRjJRWXJkaV9UQ0tHSE5zTm1mbE9sUVh1eHhIVjVOVjJFQ1JWUm9OMjlBREZHUnhHT04yTElmUUFMM21fWlBhMkZ1YzVnOEVTd2JDTE1vdjJHNGhIRERWVjJUdXNTSXh2ZmpBckNwN2ZzZk1BeHJUcThidkJRSS1D?oc=5" target="_blank">CAR-T manufacturing & delivery for multiple myeloma patients</a>&nbsp;&nbsp;<font color="#6f6f6f">Johnson & Johnson</font>
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQYlBoSHllQTFSb18wVW5meHB0ZnJhbEd6WkJjSnlkY1FleFpRMG5rOElueW5VZjFuSzBiR2FFeDMxSTcyb3J2b1gwTkZVOW1mRWlXSkZWWElkS3BLYXNZeUd5MzlLNlJMaVdnTUtzcm5XLU5nTjY0c0RpdHhMeXoxWVFaaEJPcllQQzNGcXR3cjFZSTU4aVRUdi16cWg0Y1d3MlRnaEtqN1JsQ1Q4SWdtT2ZleDlpN3E2bkF6Rg?oc=5" target="_blank">Addressing CAR-T Therapy Challenges in Extramedullary Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Hematology Advisor</font>
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxPR0dhay02RkNsaDhZYlNKSmtpR0hPcGxidGVZUS1ob2E5algwSkQ0T2dUenpXYlhuYy1QdV8tdDhNOHpsYnY3X3ZuZ1h3MU1wMGRCc2NWOUszYTZRTGwyZEdxSFY5cHlGQlVLd0tNRVU1VzM4elkxSldRbkdfcHNMQ2lrWHFYLXQ4REh1WGgtZlJMeDJGUWp1ZEMzS0hqX1pEdGhxd2pMdXBKeHY4NF9tSFdwbnF3VUxzdklvcFctbDNjQVN0X3RUbE1YZmpQYVRieDM0TU9ubmQxVEE2dnc?oc=5" target="_blank">Off-the-Shelf CAR T-Cell Therapy Produces Deep, Durable Responses in Heavily Pretreated Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">The ASCO Post</font>
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQaXRhTnJ2b3d5MnNtelIyT0JGeG52ZlVOQlhndTlZbnpzVFhxLU4yaFNtOFJ4UV9MR21jbjQ5VFowX0doM2ZvSlJXZTFGWWx3cHlUQTBQdEcycFlPSkZhaFdCTGlJUm9aUF9qRmZkSWdZNnp1ekZWZG9oUG1TNy00YU9uNFZWLThBOHBxUVJ3SW1tVGxhMVp6UlI4UHpPZzh6RndVU2JMVEtLNGIweXM1Zy1PYW4tRWlIMVBWVWhoRUJLYWVpUjRz?oc=5" target="_blank">FDA gives go-ahead for trial testing CAR T-cell therapy for progressive MS</a>&nbsp;&nbsp;<font color="#6f6f6f">Multiple Sclerosis News Today</font>
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPN0JOZXFFS0dfUzRDY2p6dnA3ZHQzc0VqUWVDTjBOM2hOTzI3VXpTZkY4TFRBNks3bFRqRi1DWldEWVJQYWpkREw2WGRReHVNQkFiNnN1UzVwQWhZeklwclJ6Q2RqWG5yZDhobFN1bzZ2bm8yd2hHalNNdlRKaWRaN0FqX3RWQmFXamZQMk9ZRnZZRUwtYi0wU0Rsa01FS0p2S1loRk5nS0w?oc=5" target="_blank">What Makes an Optimal CAR T-Cell Therapy Candidate in Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9lNUZBUUVpSER1YWNvYmhTa21EX1RSQktfanJDY3ZEQV9pVGp4dmNraWhqOUZ6NUdBVllzX1cwY0FCYlpYWHJMSEM5WW93WUZ2eVptSWR4WXdLRWxFOVpj?oc=5" target="_blank">Lesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNcGtxbzg0M1pSRzhBNUZzdmt5aTM0MUlxbVcyMXc5azZldnJBeU9ZQnFENDR2WTktZFB5WXRQZUhWMnFsZGZrMTZkRzN6Y0xGQWtuX3g2emJhYUNsakMxa0Z0c0Y3dmJMZVVrZjFGd0l3eHJVSmRadXNtcUNMYlhjZWtFMzVBSGt6LUdCNEVBeGpGS0I1M0R2c0RrZ3U5M19ac2Z2Xzd6OG1uYXM2YThjUWxoV2V3UVBES2hwZm5jdw?oc=5" target="_blank">Longer-Term Data Continue to Support Earlier Integration of CAR T-Cell Therapy in R/R Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">OncLive</font>
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPX2tCQVZobjhPbDcyUHU3cThtc3hKQVdUcXM5V29vazc3UUFJNFpiUG9yVm5PTWZFblJsaWVHMnVxZ2FfcVVrREJ0V3JJZlVsRUxCZ210bzQxSEtGWUpjMm1RN0EzQ2tBYy14NTkxc0d6TjVMTWUwMXBiYWhPZkJmdXdSUHdKcTEzX09pTHRRTzc1ZlJBZDA5YkpiT2xOcGZXTkE0X3RRdF9Ca1FRS3YtRURoaTRzamNGQjNkb01yVzE?oc=5" target="_blank">Individualizing CAR T-Cell Therapy vs Bispecific Antibodies in Relapsed Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFB3dXhHeFB5OVl1TndBX3kydWM1VDhUOUQzNjc2NlV3bUhxWURqakYxelhmYS1nZGdpWldOZDFwNVhXRnhRaFhvUmIwT1FPaUVvZldlOWtsOWpDUThqX2Zv?oc=5" target="_blank">Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxNeTlNOEgzZ0Z0cGZ3RlNVNllZNENvN2JDZVB2Qk5jT3BsSHpCSnk2ZkpSNU1EVGY3ZkQtODVFNDg4N0tFQ0RMTzBYQmVkUTdxOERxTXVTdUZoUF9jdXBNdUZzaFo1NDlDTnlOczYwOEtvQzBPVC01UmIzR2MxV1ByT0pzYlpmREItdnRPQ25Fb3VnMUxHWlBIczVmVkdjVEp3dS1CU3ljbFFzcWRiVXhwdkVzX1dZX21WZlZvZXowcFNNLU1LZWNCYllGdVBnM0k?oc=5" target="_blank">Debate: CAR-T Cell Therapy Versus BCMA Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxOUjlXNjZzRnFBX1ZrX0lYSXNEWFNpRFZuSG1RTHNuMlh5R0JqMXUxUTFNUEtab1ZWOXN0YkhSeUd0V0RZNzZZWVplRXl6VXpvdVJOWU5WQ0ZXQ0FqRjFDNmVjbmFaMlpNRUUxejZwejVpbEItbWtqSWlXS0hqSEZCbXJvbGRvTEEteTQ5R2xNMExFeG9xTDNmQUUwVlVSclFEeDhZU0JNVEljeXp6?oc=5" target="_blank">Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPWFhrdzJBZ0VYdjBlVXRsMXFnY2VUeUV6NHpEVTR1enpHWURIX05RZjgzNGpwX2tCcnp2UEZENjF4YXdoMVlkVEhsZ215b1FmaXRLUEcxUW1Ma3lyMUpNVzF0cy1oMHhXeVBEcmxlNktCYjFoVUZIdFc1b3l6aW8xRVpPWV9xVlZSUTRpTzluckEteXNKUFVaZlFNYkxoSHJwS0VzTFl3bw?oc=5" target="_blank">Why CAR T-Cell Therapy Should Precede Bispecifics in Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQYk5wcEpISE5vWFBIVlQ1UVBmM1NJLWJJNTl0VWRmVHlUZm5TQmxXWUlrT1l1OTdaWExUR2JNRzZIM09GRXROQl9RVWdEVXhyMUtvdEl1eG9oTWh4bDVUUmFEYUJ4Y1N2VVBwUHJSd0JpSS0tbjlkX1d6Z0dsWXpmdXFfek15MTNvNGx2RW80UC1QNXlqSkdCaDdmRzZubWFvcEttaU95UDNzU05LZ2c?oc=5" target="_blank">Where Do CELMoDs Fit With CAR T Cells and Bispecifics in Multiple Myeloma?</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNZVVONllBamVnTms0Mng5ZUFGT1UtQU13WHgzMXdHZVRzS3JlakRPZGxweTAtOF9xVUlpc2RwbGtsNXZUdXo2S2swTzVCOGtiaVFGNGVCbHI3OFlITkRaWEJUV254MmdjQkI3S0hrcGRSbFk1c1hPRDE4VmhuVzljdnBMRW1QMzlYRnhOZDN4Zlk0Sl9GZTJVSFYwM29ScnVoWlZoRkhKQjU?oc=5" target="_blank">BCMA CAR T-Cell Therapy Improves OS Vs Teclistamab in Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPQTBzUTlWd2xOX3J3VU55M0VnTUswTXZWcVVRRXdnRG1RT0lRNHlvd2lhZU1DSTNMZWtnbFBvYlNVWVlWcVRzZ0JITTg0NHV1ZTZ6Ym0wVUF1TVM3WE9uN0xqQlhqR2R2S3JtZGdSZEZsbHFGTHVFeG13NUozRHhQdEV6dGZRaElxVTVrYkUxUWZ6eXpsYU80aVBGTS13MU9GTmV1dDZPUWU?oc=5" target="_blank">Weighing Bispecific Antibodies Against CAR T Cells in Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNeVV0eVhVQ3VKZTJzTlZYWlVYaHJ5SHQybU96aXFWVE1ocEtCT1JDTGs4aG5aQ2JRSW5MbjZlLWFGM0NyUDVfUXBzWkZnYnVtdHNCdm1oWU1lSTBONlVsMFhCaGt0M3R5R3dXZVdYeHNVR2Rvam5WZlROTWNPMC1UTmFWZDQzQ25xT1U0XzAyWXkweWdHUFdldEhNUWdOY3B0TE9leHdMSl94V0lpcVE?oc=5" target="_blank">What Are The Biggest Misconceptions About CAR T Cells in Multiple Myeloma?</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxQdWJTUG5DTHZSbGRCc3BaWFVrRzEtSnFWdDhGeXBaX1VjalZSVmt4cW9GTl83MlZrQnF5V2JQNVBudENBa1BiWUMwUEx5MmtleThMXzlRVDJSZmFSMzI4cF9kdURrLXBhcDV4blZpTng4YlhtOFAtaWNWU1JmcW9HSmRMX2QzeGs4eV9VNGtGdVhBZE5n?oc=5" target="_blank">Reflecting on CAR T for First Relapse in Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Targeted Oncology</font>
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOYlF3R25lcV9JanBzS1JibHBKaUdRNnVDX0RpOHFPc1dBR19RRXVva0tXUHlSdTNZVjRuM2FjQ0tENnlScnNXVmtfRjVhTXFZYVllcWR0UnlEcmpkX2libG8zZncyRF9vRURDMFpzS3ZrZ2pSODdmNFNtWlIwbHFVZFJnM1kxYm90VmtiN2ZCV25oUC12MEJaUzhxbVFQcjZudEJsaE1Kc1NfZkxIWTVXTmY4MTF0ODNLdVJ0ckdDaXo?oc=5" target="_blank">High-Risk Smoldering Multiple Myeloma: BCMA-Directed CAR T-Cell Therapy Shows Activity</a>&nbsp;&nbsp;<font color="#6f6f6f">The ASCO Post</font>
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPQ3kyYmR2V0prWGh5WmE5cUxjNm5EOVZ2QnkyVnJDNUxuRURhVmJUWFROdEVqNlk3aUNNVTc1U1BtZXZRWmtVZGgtbjV2OE5EVU9aZFNDbjgyRmJYTC1QU1BZSHZKN2dOamx1N3ZZenpKdWg3bl9EcllER0U0Zk9XWkF1VzlobmF6dFA3akZVRmpXVU1rQjlKWjRtUnRnTHlMcUtwUE5zMmg?oc=5" target="_blank">What Does Practical CAR T Cell Use Look Like in Multiple Myeloma Care?</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxQWDJRT3JxOUhxVFJqSExOSVV6TnJHcEFsM01wRGh1QWNTbkV1aXpFNHZXWkVUcUZyVkJwOW9HY3Z4TXltSS04S2lkdi1JaVlHcVFfTE02cm5RcF9MQWRsc2trT3d6UmpZMzQyWEdkVmlxQ3p4NmdONEloRFNISWVzRDJRQWlFUEE?oc=5" target="_blank">Novel CAR-T therapy shows promising safety and durable responses in hard-to-treat multiple myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Medical Xpress</font>
<a href="https://news.google.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?oc=5" target="_blank">Novel CAR-T Therapy for Hard-to-Treat Multiple Myeloma Shows Promising Safety and Durable Responses | Newswise</a>&nbsp;&nbsp;<font color="#6f6f6f">Newswise</font>
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxQWHotR2RZVnQ1WXpmYl9SaTFSemtVMG5aeHVsemFOSF9kc0kwM1dYTmJlMUt2cVZ4MG45YVBTbXhWWmNkWEkwOURLRWg3RWcwbzRSOWwyeXRObFNXLVlEU0dSdzdiSjcxb2QySVltWHE0a25pa0Zmb1pPd00tMjFPNGlKOHNTWmVEY2lRcHNpanlOUE4wbGExcEdiMXhqOGh3ak5MZjZGUHRveW9jRmFMYWczaVN3XzczZ1J3cGwyN2xVSkdFUlREVmZ4R25IeldEc3RZaA?oc=5" target="_blank">Bristol Myers Squibb Reports Positive Results for CAR T-Cell Therapy in Heavily Pretreated Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Cure Today</font>
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxON2N4dERJdE5FUHZpdFNMSmgzdzY4RkxRZmFNemN3VTU1VXdpdDk3VlEtdGEwOGxHb252aGxEUVlPZm1fUThjR1k4S09QdVB2NlRVRHljOG5IVnBNUmtZMlpxR0dVc1RJbmMwVnRrbHBSNHhHSlI0eVRHbWt5N01YRG9qLWFESHJydG1qaW1sR2stYWNJQkJRcm8xSXN5SnM5dnBTV0dPVmU4RnVQamw2bUc1dmFQRXc3eEJ6OUNfVDFOa3N2ME82Q2JPREFiVzB4Rmk3QVpITVdhQ2lGN2J4Mg?oc=5" target="_blank">Sequencing CAR T-Cell Therapy and Bispecific Antibodies at First Relapse in Relapsed/Refractory Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPY05WQ1lrUlhIR3J3TXctWmVvUHBMQ21nV2NscDdmRS1tQzRFc0tSRFMwSlhrYWR2V2QzQjhkSXpJdXBzbnVQdVQ1RGtlNUljUm9UdXdLV3Z3MDI0NFNXdFo1eDgyTjBiYkptcUxpem52VWZJLUJxM1hRUXhnajVfZHpMYzFiZ3FFN25VR1BBVVlQSHRXbzZZRFZQWldEdV81a0E?oc=5" target="_blank">CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">OncLive</font>
<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxQdFY2VGVkY2NpY3lTaXl3eGhrS2g5aENsMklJUTZZWGs0bC1ITUtsNVRoZVJLb1hPZUg5bGZQR2Q3U09ybGNmMmQtUmZJLWZLUEJsMHYtUEZhTDBOTlNubWFRbDFxX1N5enR6Nk1LaG5BakFPMkdiSlFvWFBiSHNTS1RPWDI?oc=5" target="_blank">Sequencing CAR T-Cell Therapy in Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">OncLive</font>
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOQlpFc29VMlhVMWlIaVc5eUxLTGpubkVQWTAyN1VBUzU3a2szXzJ5QlhsOFVpN3NYMmtKMG9NVldWb0dNZVBSLXMxNWNnaEdsdkxyVW5GM0x5Y2xQc3ZBdWZzM2ZJZ1ZEdnVkUWxhb1ppc1B0cnk4Ti1WNEkxczBQc0w4SnJ5LWY4U1RZdGtMa0UtMU5tczBEYmJvUlVqalJna2c0SkR2b1R5Z0VjWE5vanFXV3dvQQ?oc=5" target="_blank">Phase 1 Data Highlight Potential Utility for In Vivo CAR T-Cell Therapy in R/R Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">OncLive</font>